Pueraria lobata Targeted Preparation Improves the Clinical Symptoms of Cervical Spondylosis by Regulating the Balance of Gut Microbiota.

Yuhang Qin,Min Tang

doi:10.1155/2022/2136807

Abstract

Background Nanotargeted preparations can enhance the safety and effectiveness of medication by altering the pharmacokinetic behavior of drugs in the human body, and Pueraria lobata is shown to be effective in the treatment of neck and back pain. Purpose This study prepared a nano-Pueraria targeted preparation, in order to analyze its effect on improving the clinical symptoms of cervical spondylosis by adjusting the balance of intestinal flora. Methods A total of 200 patients with cervical spondylosis admitted to the Affiliated Hospital of Nanjing University of Chinese Medicine were enrolled and divided into an observation group and a control group. The control group was given Tuina therapy, and the observation group was given nano-Pueraria targeted preparation + Tuina therapy. The clinical symptoms and intestinal microflora of the two groups were examined before intervention. Results It was found that the markedly effective of treatment efficacy of the observation group (98%) was higher than that of the control group (78%) after 15 days of intervention, and the clinical symptoms were obviously fewer than those of the control group. The distribution of gut microbiota showed that there were significant differences in the composition of gut microbiota between the two groups. Compared with the control group, the abundance of Firmicutes in the observation group was significantly higher, while the abundance of Bacteroidetes and Proteobacteria was significantly lower. Conclusion The targeted preparation of nano-Pueraria can improve the clinical symptoms of patients with cervical spondylosis by adjusting the balance of gut microbiota.

Highlights

Cervical spondylosis refers to the degenerative changes of the cervical intervertebral disc and its accessory structures, as well as the corresponding symptoms and signs caused by the secondary degeneration of the intervertebral joints that stimulate or compress the spinal cord, nerves, and blood vessels
The observation group had more cases with markedly effective and a lower incidence of adverse reaction rate compared with the control group. These results indicate that the targeted preparation of nano-Pueraria can significantly improve the clinical symptoms of patients with cervical spondylosis, which further proves that nanotargeted preparations have good sustained- and controlled-release drug delivery and can enhance the safety and effectiveness of medication by changing the pharmacokinetic behavior of drugs in the human body
After 15 days of treatment, the abundance of the phylum Firmicutes increased and the abundance of Bacteroidetes and Proteobacteria decreased in the observation group, versus the control group. These results suggest that the targeted preparation of nanoPueraria can improve the clinical symptoms of patients with cervical spondylosis by regulating the intestinal flora

Summary

Introduction

Cervical spondylosis refers to the degenerative changes of the cervical intervertebral disc and its accessory structures, as well as the corresponding symptoms and signs caused by the secondary degeneration of the intervertebral joints that stimulate or compress the spinal cord, nerves, and blood vessels. Research has pointed out that many patients with cervical spondylosis who have not taken any drugs complain of gastrointestinal symptoms [2]. This phenomenon, which indicates a direct or indirect relationship between the neck and stomach, is called “cervical gastric syndrome.”. This study prepared a nano-Pueraria targeted preparation, in order to analyze its effect on improving the clinical symptoms of cervical spondylosis by adjusting the balance of intestinal flora. The targeted preparation of nano-Pueraria can improve the clinical symptoms of patients with cervical spondylosis by adjusting the balance of gut microbiota

Methods

Discussion

Conclusion